CBD for Sleep in People With HIV

Summary

This study will obtain preliminary information about whether, and at what dose, cannabidiol (CBD) may help with insomnia in people living with human immunodeficiency virus (HIV). The study will be a 5-week randomized, double-blind placebo-controlled phase II trial using daily oral CBD doses between 50mg and 600mg. Sleep problems will be measured using a wrist-worn device and by self-report. Performance on tests of thinking skills will be compared before and after CBD/placebo treatment. Positive study results will provide support for the use of CBD as a potential treatment for insomnia.

Timeline

Start

2021-04-01

Primary completion

2023-08-31

Completion

2023-08-31

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulties enrolling eligible participants”

Drugs

Indications